|Mrs. Rachel K. King||Chief Exec. Officer and Director||772.42k||N/A||58|
|Mr. Brian M. Hahn||Chief Financial Officer and Sec.||458.38k||N/A||43|
|Dr. John L. Magnani Ph.D.||Chief Scientific Officer, Sr. VP of Research and Director||529.58k||N/A||64|
|Dr. Helen M. Thackray M.D., FAAP||Chief Medical Officer and Sr. VP of Clinical Devel.||577.27k||N/A||49|
|Mr. Henry Flanner||VP of Technical Operations||N/A||N/A||N/A|
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.